Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1793, Issue 5, 2009, Pages 764-771

  Qian, Yi Hua ^a,b   Xiao, Qingli ^b   Chen, Hong ^b   Xu, Jan ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bcl xL; C6 glioma; Camptothecin; Dexamethasone; Stat5

Indexed keywords

ANTIBODY; CAMPTOTHECIN; CASPASE 3; DEXAMETHASONE; DNA; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; PROTEIN BCL XL; SMALL INTERFERING RNA; STAT5 PROTEIN; TRANSCRIPTION FACTOR;

ADENOVIRUS INFECTION; ANIMAL CELL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL DEGENERATION; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL MOTION; CELL PROTECTION; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; DNA FRAGMENTATION; DRUG BINDING; DRUG MECHANISM; GENE; GENE OVEREXPRESSION; GLIOMA; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; STEM CELL; THERAPY EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CAMPTOTHECIN; CELL LINE, TUMOR; DEXAMETHASONE; DNA FRAGMENTATION; GLIOMA; RATS; RECEPTORS, GLUCOCORTICOID; RNA INTERFERENCE; STAT5 TRANSCRIPTION FACTOR;

ADENOVIRIDAE;

EID: 67349162522     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2009.01.017     Document Type: Article

References (74)

1. Rutz H.P., and Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol. Ther. 3 (2004) 715-718
2. Schmidt S., Rainer J., Ploner C., Presul E., Riml S., and Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 11 (2004) S45-S55
3. Rutz H.P. Effects of corticosteroid use on treatment of solid tumours. Lancet 360 (2002) 1969-1970
4. Weinstein R.S. Glucocorticoid-induced osteoporosis. Rev. Endocr. Metab. Disord. 2 (2001) 65-73
5. Weinstein R.S., Chen J.R., Powers C.C., Stewart S.A., Landes R.D., Bellido T., Jilka R.L., Parfitt A.M., and Manolagas S.C. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109 (2002) 1041-1048
6. Berg M.N., Dharmarajan A.M., and Waddell B.J. Glucocorticoids and progesterone prevent apoptosis in the lactating rat mammary gland. Endocrinology 143 (2002) 222-227
7. Feng Z., Marti A., Jehn B., Altermatt H.J., Chicaiza G., and Jaggi R. Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J. Cell Biol. 131 (1995) 1095-1103
8. Sasson R., and Amsterdam A. Pleiotropic anti-apoptotic activity of glucocorticoids in ovarian follicular cells. Biochem. Pharmacol. 66 (2003) 1393-1401
9. Sasson R., Shinder V., Dantes A., Land A., and Amsterdam A. Activation of multiple signal transduction pathways by glucocorticoids: protection of ovarian follicular cells against apoptosis. Biochem. Biophys. Res. Commun. 311 (2003) 1047-1056
10. Ikegami T., Matsuzaki Y., Al Rashid M., Ceryak S., Zhang Y., and Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol. Cancer Ther. 5 (2006) 68-79
11. Hammer S., Sauer B., Spika I., Schraut C., Kleuser B., and Schafer-Korting M. Glucocorticoids mediate differential anti-apoptotic effects in human fibroblasts and keratinocytes via sphingosine-1-phosphate formation. J. Cell. Biochem. 91 (2004) 840-851
12. Viegas L.R., Vicent G.P., Baranao J.L., Beato M., and Pecci A. Steroid hormones induce bcl-X gene expression through direct activation of distal promoter P4. J. Biol. Chem. 279 (2004) 9831-9839
13. Das A., Banik N.L., Patel S.J., and Ray S.K. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol. Cancer 3 (2004) 1-10
14. Gorman A.M., Hirt U.A., Orrenius S., and Ceccatelli S. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells. Neuroscience 96 (2000) 417-425
15. Ni Chonghaile T., Concannon C.G., Szegezdi E., Gorman A.M., and Samali A. Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. Apoptosis 11 (2006) 1247-1255
16. Sur P., Sribnick E.A., Patel S.J., Ray S.K., and Banik N.L. Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. Glia 50 (2005) 160-167
17. Ochiai H., Pernell C.T., Archer G.E., Chewning T.A., McLendon R.E., Friedman H.S., and Sampson J.H. Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurol. Med. Chir. (Tokyo) 46 (2006) 485-489 discussion 489-490
18. Piette C., Munaut C., Foidart J.M., and Deprez M. Treating gliomas with glucocorticoids: from bedside to bench. Acta Neuropathol. 112 (2006) 651-664
19. Ito S., Rachinger W., Stepp H., Reulen H.J., and Stummer W. Oedema formation in experimental photo-irradiation therapy of brain tumours using 5-ALA. Acta. Neurochir. (Wien) 147 (2005) 57-65 discussion 65
20. Shapiro W.R., and Posner J.B. Corticosteroid hormones. Effects in an experimental brain tumor. Arch. Neurol. 30 (1974) 217-221
21. Hossmann K.A., Hurter T., and Oschlies U. The effect of dexamethasone on serum protein extravasation and edema development in experimental brain tumors of cat. Acta Neuropathol. (Berl) 60 (1983) 223-231
22. Jarden J.O., Dhawan V., Moeller J.R., Strother S.C., and Rottenberg D.A. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann. Neurol. 25 (1989) 239-245
23. Shapiro W.R., Hiesiger E.M., Cooney G.A., Basler G.A., Lipschutz L.E., and Posner J.B. Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma. J. Neuro-oncol. 8 (1990) 197-240
24. Machein M.R., Kullmer J., Ronicke V., Machein U., Krieg M., Damert A., Breier G., Risau W., and Plate K.H. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol. Appl. Neurobiol. 25 (1999) 104-112
25. Cuevas P., Diaz-Gonzalez D., Sanchez I., Lozano R.M., Gimenez-Gallego G., and Dujovny M. Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells. Neurol. Res. 28 (2006) 127-130
26. de Groot R.P., Raaijmakers J.A., Lammers J.W., and Koenderman L. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol. Cell Biol. Res. Commun. 3 (2000) 299-305
27. Rahaman S.O., Harbor P.C., Chernova O., Barnett G.H., Vogelbaum M.A., and Haque S.J. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21 (2002) 8404-8413
28. Kim R., Emi M., and Tanabe K. Caspase-dependent and -independent cell death pathways after DNA damage (review). Oncol. Rep. 14 (2005) 595-599
29. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem. Biophys. Res. Commun. 333 (2005) 336-343
30. Bovolenta C., Pilotti E., Mauri M., Turci M., Ciancianaini P., Fisicaro P., Bertazzoni U., Poli G., and Casoli C. Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factor. Blood 99 (2002) 224-231
31. Packham G., White E.L., Eischen C.M., Yang H., Parganas E., Ihle J.N., Grillot D.A., Zambetti G.P., Nunez G., and Cleveland J.L. Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev. 12 (1998) 2475-2487
32. Zhang Y., Kirken R.A., Furian L., Janczewska S., Qu X., Hancock W.W., Wang M., Tejpal N., Kerman R., Kahan B.D., et al. Allograft rejection requires STAT5a/b-regulated antiapoptotic activity in T cells but not B cells. J. Immunol. 176 (2006) 128-137
33. Battle T.E., and Frank D.A. The role of STATs in apoptosis. Curr. Mol. Med. 2 (2002) 381-392
34. Calo V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197 (2003) 157-168
35. Dumon S., Santos S.C., Debierre-Grockiego F., Gouilleux-Gruart V., Cocault L., Boucheron C., Mollat P., Gisselbrecht S., and Gouilleux F. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene 18 (1999) 4191-4199
36. Garcon L., Rivat C., James C., Lacout C., Camara-Clayette V., Ugo V., Lecluse Y., Bennaceur-Griscelli A., and Vainchenker W. Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 108 (2006) 1551-1554
37. Grad J.M., Zeng X.R., and Boise L.H. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr. Opin. Oncol. 12 (2000) 543-549
38. Sanchez-Ceja S.G., Reyes-Maldonado E., Vazquez-Manriquez M.E., Lopez-Luna J.J., Belmont A., and Gutierrez-Castellanos S. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer 54 (2006) 163-168
39. Meyer S., Eden T., and Kalirai H. Dexamethasone protects against cisplatin-induced activation of the mitochondrial apoptotic pathway in human osteosarcoma cells. Cancer Biol. Ther. 5 (2006) 915-920
40. Duke R.C., Cohen J.J., and Chervenak R. Differences in target cell DNA fragmentation induced by mouse cytotoxic T lymphocytes and natural killer cells. J. Immunol. 137 (1986) 1442-1447
41. Leist M., Gantner F., Bohlinger I., Germann P.G., Tiegs G., and Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J. Immunol. 153 (1994) 1778-1788
42. Xu J., Chen S., Ku G., Ahmed S.H., Xu J., Chen H., and Hsu C.Y. Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J. Cereb. Blood Flow Metab. 21 (2001) 702-710
43. An G., Lin T.N., Liu J.S., Xue J.J., He Y.Y., and Hsu C.Y. Expression of c-fos and c-jun family genes after focal cerebral ischemia. Ann. Neurol. 33 (1993) 457-464
44. Xu J., He L., Ahmed S.H., Chen S.W., Goldberg M.P., Beckman J.S., and Hsu C.Y. Oxygen-glucose deprivation induces inducible nitric oxide synthase and nitrotyrosine expression in cerebral endothelial cells. Stroke 31 (2000) 1744-1751
45. Xu J., Fan G., Chen S., Wu Y., Xu X.M., and Hsu C.Y. Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res. Mol. Brain Res. 59 (1998) 135-142
46. Salminen A., Liu P.K., and Hsu C.Y. Alteration of transcription factor binding activities in the ischemic rat brain. Biochem. Biophys. Res. Commun. 212 (1995) 939-944
47. Onishi M., Nosaka T., Misawa K., Mui A.L., Gorman D., McMahon M., Miyajima A., and Kitamura T. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18 (1998) 3871-3879
48. Nosaka T., Kawashima T., Misawa K., Ikuta K., Mui A.L., and Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 18 (1999) 4754-4765
49. Sharma V., Lansdell T.A., Peddibhotla S., and Tepe J.J. Sensitization of tumor cells toward chemotherapy: enhancing the efficacy of camptothecin with imidazolines. Chem. Biol. 11 (2004) 1689-1699
50. Wadkins R.M., Bearss D., Manikumar G., Wani M.C., Wall M.E., and Von Hoff D.D. Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity. Curr. Med. Chem. Anticancer Agents 4 (2004) 327-334
51. Yoshida A., Takemura H., Inoue H., Miyashita T., and Ueda T. Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res. 66 (2006) 5772-5780
52. Rieger J., Durka S., Streffer J., Dichgans J., and Weller M. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. Eur. J. Pharmacol. 365 (1999) 301-308
53. Schorr K., and Furth P.A. Induction of bcl-xL expression in mammary epithelial cells is glucocorticoid-dependent but not signal transducer and activator of transcription 5-dependent. Cancer Res. 60 (2000) 5950-5953
54. Stocklin E., Wissler M., Gouilleux F., and Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature 383 (1996) 726-728
55. Wyszomierski S.L., and Rosen J.M. Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor. Mol. Endocrinol. 15 (2001) 228-240
56. Oh H.Y., Namkoong S., Lee S.J., Por E., Kim C.K., Billiar T.R., Han J.A., Ha K.S., Chung H.T., Kwon Y.G., Lee H., and Kim Y.M. Dexamethasone protects primary cultured hepatocytes from death receptor-mediated apoptosis by upregulation of cFLIP. Cell Death Differ. 13 (2006) 512-523
57. Chauhan D., Li G., Hideshima T., Podar K., Mitsiades C., Mitsiades N., Catley L., Tai Y.T., Hayashi T., Shringarpure R., Burger R., Munshi N., Ohtake Y., Saxena S., and Anderson K.C. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 102 (2003) 3379-3386
58. Baumann S., Dostert A., Novac N., Bauer A., Schmid W., Fas S.C., Krueger A., Heinzel T., Kirchhoff S., Schutz G., and Krammer P.H. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood 106 (2005) 617-625
59. Beato M., Herrlich P., and Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 83 (1995) 851-857
60. Novac N., Baus D., Dostert A., and Heinzel T. Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter. FASEB J. 20 (2006) 1074-1081
61. Hendry L., and John S. Regulation of STAT signalling by proteolytic processing. Eur. J. Biochem. 271 (2004) 4613-4620
62. Machuca C., Mendoza-Milla C., Cordova E., Mejia S., Covarrubias L., Ventura J., and Zentella A. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell. Biol. 7 (2006) 1-12
63. Mendoza-Milla C., Machuca Rodriguez C., Cordova Alarcon E., Estrada Bernal A., Toledo-Cuevas E.M., Martinez Martinez E., and Zentella Dehesa A. NF-kappaB activation but not PI3K/Akt is required for dexamethasone dependent protection against TNF-alpha cytotoxicity in L929 cells. FEBS Lett. 579 (2005) 3947-3952
64. Zhang C., Wenger T., Mattern J., Ilea S., Frey C., Gutwein P., Altevogt P., Bodenmuller W., Gassler N., Schnabel P.A., Dienemann H., Marme A., Hohenfellner M., Haferkamp A., Pfitzenmaier J., Grone H.J., Kolb A., Buchler P., Buchler M., Friess H., Rittgen W., Edler L., Debatin K.M., Krammer P.H., Rutz H.P., and Herr I. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol. Ther. 6 (2007) 278-287
65. Gascoyne D.M., Kypta R.M., and Vivanco M.M. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J. Biol. Chem. 278 (2003) 18022-18029
66. Wada T., Pippin J.W., Marshall C.B., Griffin S.V., and Shankland S.J. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J. Am. Soc. Nephrol. 16 (2005) 2615-2625
67. Wanke I., Schwarz M., and Buchmann A. Insulin and dexamethasone inhibit TGF-beta-induced apoptosis of hepatoma cells upstream of the caspase activation cascade. Toxicology 204 (2004) 141-154
68. Fan W., Sui M., and Huang Y. Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Curr. Med. Chem. 11 (2004) 403-411
69. Huang Y., Johnson K.R., Norris J.S., and Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 60 (2000) 4426-4432
70. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8 (2004) 409-422
71. Yamashita H., Nishio M., Fujii Y., and Iwase H. Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci. 95 (2004) 662-665
72. Baskiewicz-Masiuk M., Masiuk M., and Machalinski B. The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines. Cell Prolif. 36 (2003) 265-278
73. Jensen J., Galsgaard E.D., Karlsen A.E., Lee Y.C., and Nielsen J.H. STAT5 activation by human GH protects insulin-producing cells against interleukin-1beta, interferon-gamma and tumour necrosis factor-alpha-induced apoptosis independent of nitric oxide production. J. Endocrinol. 187 (2005) 25-36
74. Kirito K., Watanabe T., Sawada K., Endo H., Ozawa K., and Komatsu N. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J. Biol. Chem. 277 (2002) 8329-8337